Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

39
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions.
BPTH

39
BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-05-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BPTH

39
Bio-Path Holdings Reports First Quarter 2018 Financial Results

2018-05-16 globenewswire
HOUSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate developments.
BPTH

59
BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BPTH

39
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

2018-04-18 globenewswire
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-clinical studies supporting the potential of prexigebersen (BP1001, liposomal Grb2 antisense), in the treatment of solid tumors in gynecologic malignancies were presented in a poster at the annual meeting of the American Association for Cancer Research (AACR), which took place in Chicago, IL.
BPTH

161
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

2018-04-06 zacks
It was a happening week for pharma stocks, Key developments this week included a new CAR-T deal for Pfizer (PFE - Free Report) , successful study results from Pfizer, Lilly (LLY - Free Report) and Allergan (AGN - Free Report) and positive regulatory updates from AstraZeneca (AZN - Free Report) .
SNOA AZN BPTH AGN AZN RB PFE

59
Bio-Path Leukemia Combo Study Shows Positive Early Data

2018-04-04 zacks
Bio-Path Holdings, Inc. announced positive interim data from phase II study (BP1001-201) on its lead pipeline candidate — prexigebersen — in combination with low-dose cytarabine (“LDAC”) for the treatment of patients with acute myeloid leukemia (“AML”) who cannot or choose not to be treated with more intensive chemotherapy.
REGN BPTH SIG LGNZZ LGND LGNYZ LGNXZ MYGN LGNDZ SIG

313
Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results

2018-04-04 seekingalpha
Bio-Path announced positive preliminary results from mid-stage study of prexigebersen (BP1001) and low-dose cytarabine in AML.
RIGL REGN AMGN GERN MYOV AZN GLMD PBYI MTFB MTFB SNY BPTH AZN MTFBF JNJ MRK CELG PFE

39
Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today

2018-04-03 investorplace
Bio-Path Holdings Inc (NASDAQ:BPTH) stock was up Tuesday on a few bits of good news from the company.
BPTH

39
Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Good morning, ladies and gentlemen and welcome to the Bio-Path Holdings Full Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we’ll open up the call for your questions.
BPTH

39
Bio-Path Holdings Reports Full Year 2017 Financial Results

2018-04-03 globenewswire
HOUSTON, April 03, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2017 and provided an update on recent corporate developments.
BPTH

39
BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-04-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
BPTH

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 09057N102